Total effective vascular compliance in patients with cirrhosis. Effects of propranolol.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Hepatology

• Publication date

  2002-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0168-8278(01)00300-2PMID 11867179
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathophysiology of Portal Hypertension

  2015cited by this paper
• β-blockers of the third generation inhibit Endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells

  2000cited by this paper
• Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells.

  2000cited by this paper
• Complications of cirrhosis. I. Portal hypertension.

  2000cited by this paper
• Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects.

  1999cited by this paper
• Carvedilol, a new nonselective beta‐blocker with intrinsic anti‐alpha1‐adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis

  1999cited by this paper
• Oxford Textbook of Clinical Hepatology

  1999cited by this paper
• Atrial natriuretic peptide antagonizes endothelin‐induced calcium increase and cell contraction in cultured human hepatic stellate cells

  1999cited by this paper
• The sympathetic nervous system in liver disease.

  1998cited by this paper
• Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems.

  1998cited by this paper
• Pulmonary vascular disorders in portal hypertension.

  1998cited by this paper
• Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and hepatopulmonary syndrome.

  1997cited by this paper
• Nitric oxide-mediated beta 2-adrenoceptor relaxation is impaired in mesenteric veins from portal-hypertensive rats.

  1996cited by this paper
• Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.

  1996cited by this paper
• Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis.

  1996cited by this paper
• Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats.

  1995cited by this paper
• Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis

  1995cited by this paper
• Clinical pharmacology, physiology and pathophysiology of superficial veins--1.

  1994cited by this paper
• Clinical pharmacology, physiology and pathophysiology of superficial veins--2.

  1994cited by this paper
• Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites

  1994cited by this paper
• Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats.

  1993cited by this paper
• Role of central blood volume in the development of sodium retention in portal hypertensive rats

  1993cited by this paper
• Total effective vascular compliance in patients with cirrhosis: A study of the response to acute blood volume expansion

  1992cited by this paper
• Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome.

  1992cited by this paper
• Pathophysiology of portal hypertension.

  1992cited by this paper
• Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition.

  1992cited by this paper
• Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium.

  1992cited by this paper
• Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation.

  1991cited by this paper
• Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage.

  1990cited by this paper
• Enhancement of portal pressure reduction by the association of isosorbide‐5‐mononitrate to propranolol administration in patients with cirrhosis

  1990cited by this paper
• Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: role of hyperglucagonism.

  1990cited by this paper
• Reduced central blood volume in cirrhosis.

  1989cited by this paper
• Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: Influence of the extent of portal‐systemic shunting

  1989cited by this paper
• Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats.

  1988cited by this paper
• Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis

  1988cited by this paper
• Reversal of adrenaline-induced increase in azygos blood flow in patients with cirrhosis receiving propranolol.

  1987cited by this paper
• Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis.

  1987cited by this paper
• Hypersensitivity of mesenteric veins to 5‐hydroxytryptamine‐ and ketanserin‐induced reduction of portal pressure in portal hypertensive rats

  1986cited by this paper
• Increased portal venous resistance hinders portal pressure reduction during the administration of β‐adrenergic blocking agents in a portal hypertensive model

  1985cited by this paper
• Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver.

  1985cited by this paper
• Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis.

  1984cited by this paper
• Effects of Propranolol on Azygos Venous Blood Flow and Hepatic and Systemic Hemodynamics in Cirrhosis

  1984cited by this paper
• Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis

  1980cited by this paper
• Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis.

  1980cited by this paper
• Wedged and free hepatic venous pressure measured with a balloon catheter.

  1979cited by this paper
• Total Effective Compliance, Cardiac Output and Fluid Volumes in Essential Hypertension

  1978cited by this paper
• Wedged and free hepatic venous pressure measured with a balloon catheter

  1978cited by this paper
• Effective Compliance of the Total Vascular Bed and the Intrathoracic Compartment Derived from Changes in Central Venous Pressure Induced by Volume Changes in Man

  1974cited by this paper
• Transection of the oesophagus for bleeding oesophageal varices

  1973cited by this paper
• Thermodilution cardiac output determination with a single flow-directed catheter.

  1972cited by this paper

• The influence of static portal pressure on liver biophysical properties.

  2023cites this paper
• [CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis].

  2022cites this paper
• Impact of Propranolol on Preventing Renal Dysfunction in Patients with Cirrhosis

  2017cites this paper
• PROBLEMAS DURANTE EL PERÍODO PERIOPERATORIO DEL TRASPLANTE HEPÁTICO: PROFILAXIS Y TRATAMIENTO

  2016cites this paper
• Influence of CYP2D6 and β2‐adrenergic receptor gene polymorphisms on the hemodynamic response to propranolol in Chinese Han patients with cirrhosis

  2016cites this paper
• Development of hyperdynamic circulation and response to β‐blockers in compensated cirrhosis with portal hypertension

  2016cites this paper
• Recent Advances in Cirrhotic Cardiomyopathy

  2015cites this paper
• Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunction.

  2015cites this paper
• Prognosis of acute variceal bleeding: Is being on beta‐blockers an aggravating factor? A short‐term survival analysis

  2015cites this paper
• Beta-blockers in liver cirrhosis

  2014cites this paper
• Liver cirrhosis.

  2014cites this paper
• Cardiopulmonary complications in chronic liver disease hypertension;

  2014cites this paper
• Comparison of Hepatic Venous Pressure Gradient and Two Models of End-stage Liver Disease for Predicting the Survival in Patients With Decompensated Liver Cirrhosis

  2012cites this paper
• Morphological and biomechanical remodeling of the hepatic portal vein in a swine model of portal hypertension.

  2012cites this paper
• Medical management of hepatorenal syndrome.

  2012cites this paper
• Regulation of the Extracellular Fluid Volume and Renal Function

  2011cites this paper
• Balancing volume resuscitation and ascites management in cirrhosis

  2010cites this paper
• REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY

  2009cites this paper
• Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.

  2009cites this paper
• Cardiac and systemic haemodynamic complications of liver cirrhosis

  2009cites this paper
• are mediated by nitric oxide

  2008cites this paper
• Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients.

  2008cites this paper
• Gastric carcinoid tumor in a patient with a past history of gastrointestinal stromal tumor of the stomach.

  2008cites this paper
• Bacterial translocation, infection and coagulation in cirrhosis and portal hypertension

  2008cites this paper
• Altered mesenteric venous capacitance and volume pooling in cirrhotic rats are mediated by nitric oxide.

  2008cites this paper
• How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers.

  2007cites this paper
• Effect of propranolol on portal pressure and systemic hemodynamics in patients with liver cirrhosis and portal hypertension: a prospective study.

  2007cites this paper
• Cardiopulmonary complications in chronic liver disease.

  2006cites this paper
• Liver cirrhosis and arterial hypertension.

  2006cites this paper
• Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension.

  2006cites this paper
• LIVER FAILURE AND LIVER DISEASE

  2005cites this paper
• Papel de la albmina en el tratamiento del sndrome hepatorrenal en la cirrosis

  2005cites this paper
• Prolonged Q-T(c) interval in mild portal hypertensive cirrhosis.

  2005cites this paper
• [Role of albumin in the treatment of hepatorenal syndrome in cirrhosis].

  2005cites this paper
• Utilidad de las técnicas hemodinámicas en el diagnostico y en el tratamiento de la hipertensión portal: nuevas aportaciones

  2004cites this paper
• Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis.

  2004cites this paper
• Hypertension and liver disease

  2004cites this paper
• New therapies for chronic hepatitis C virus infection

  2004cites this paper
• Volume adaptation in chronic liver disease: on the static and dynamic location of water, salt, protein and red cells in cirrhosis

  2004cites this paper
• Current status of immunomodulatory therapies in HCV infection

  2004cites this paper
• β-Adrenergic Blockade Affects Initial Drug Distribution Due to Decreased Cardiac Output and Altered Blood Flow Distribution

  2004cites this paper
• The Effects of Desflurane and Propofol on Portosystemic Pressure in Patients with Portal Hypertension

  2003cites this paper
• Review article: volume expansion in patients with cirrhosis

  2002cites this paper
• Review article: albumin for circulatory support in patients with cirrhosis

  2002cites this paper